"Mixed Results For Shorter DAPT In ACS Patients" - Nicole Lou
Although a shorter duration of dual antiplatelet therapy (DAPT) was non-inferior to the standard regimen among acute coronary syndrome (ACS) patients getting drug-eluting stents (DES) in the SMART-DATE trial, a signal of excess MIs led investigators to caution against the interpretation that the two are equally safe. Prolonged DAPT in ACS patients without excessive risk of bleeding should remain the standard of care, they said, noting that 12 months of DAPT is currently recommended for this population. "It's interesting that you met the primary endpoint, but you are advising against change in practice," said ACC session panelist Roxana Mehran, MD, professor of medicine, cardiology, population health science and policy, and director of interventional cardiovascular research and clinical trials at the Zena and Michael A. Weiner Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai.
- Roxana Mehran, MD, Professor, Medicine, Cardiology, Population Health Science and Policy, Director, Interventional Cardiovascular Research and Clinical Trials, Zena and Michael A. Weiner Cardiovascular Institute, Icahn School of Medicine at Mount Sinai
Coronary Stent Patients May Not Need Long-Term Aspirin
Sep 26, 2019 View All Press Releases